NASDAQ: GLUE
Monte Rosa Therapeutics Inc Stock

$6.88+0.04 (+0.58%)
Updated Feb 6, 2025
GLUE Price
$6.88
Fair Value Price
$1.60
Market Cap
$422.68M
52 Week Low
$3.21
52 Week High
$12.40
P/E
-3.78x
P/B
2.06x
P/S
29.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.98M
Earnings
-$119.39M
Gross Margin
100%
Operating Margin
-794.69%
Profit Margin
-797.3%
Debt to Equity
0.53
Operating Cash Flow
-$57M
Beta
1.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GLUE Overview

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company developing of novel small molecule precision medicines that use the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways. Monte Rosa Therapeutics was incorporated in 2019 and is headquartered in Boston, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine GLUE's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

C
Value
B
Growth
C
Momentum
C
Sentiment
D
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
GLUE
Ranked
#33 of 560

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important GLUE news, forecast changes, insider trades & much more!

GLUE News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLUE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GLUE ($6.88) is overvalued by 330.91% relative to our estimate of its Fair Value price of $1.60 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GLUE ($6.88) is not significantly undervalued (330.91%) relative to our estimate of its Fair Value price of $1.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GLUE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GLUE due diligence checks available for Premium users.

Valuation

GLUE fair value

Fair Value of GLUE stock based on Discounted Cash Flow (DCF)

Price
$6.88
Fair Value
$1.60
Overvalued by
330.91%
GLUE ($6.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLUE ($6.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLUE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GLUE price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-3.78x
Industry
-152.12x
Market
31.69x

GLUE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.06x
Industry
5.03x
GLUE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GLUE's financial health

Profit margin

Revenue
$9.2M
Net Income
-$23.9M
Profit Margin
-258.9%
GLUE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GLUE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$315.1M
Liabilities
$109.6M
Debt to equity
0.53
GLUE's short-term assets ($251.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLUE's short-term assets ($251.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLUE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$21.0M
Investing
$37.7M
Financing
$15.0k
GLUE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GLUE vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
GLUEB$422.68M+0.58%-3.78x2.06x
ZVRAD$420.60M-3.79%-4.00x6.03x
ATXSD$420.43M-2.10%-3.43x1.23x
RGNXC$417.66M0.00%-1.68x1.39x
RIGLA$429.63M+6.79%97.56x-29.35x

Monte Rosa Therapeutics Stock FAQ

What is Monte Rosa Therapeutics's quote symbol?

(NASDAQ: GLUE) Monte Rosa Therapeutics trades on the NASDAQ under the ticker symbol GLUE. Monte Rosa Therapeutics stock quotes can also be displayed as NASDAQ: GLUE.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.

What is the 52 week high and low for Monte Rosa Therapeutics (NASDAQ: GLUE)?

(NASDAQ: GLUE) Monte Rosa Therapeutics's 52-week high was $12.40, and its 52-week low was $3.21. It is currently -44.52% from its 52-week high and 114.33% from its 52-week low.

How much is Monte Rosa Therapeutics stock worth today?

(NASDAQ: GLUE) Monte Rosa Therapeutics currently has 61,436,740 outstanding shares. With Monte Rosa Therapeutics stock trading at $6.88 per share, the total value of Monte Rosa Therapeutics stock (market capitalization) is $422.68M.

Monte Rosa Therapeutics stock was originally listed at a price of $21.18 in Jun 24, 2021. If you had invested in Monte Rosa Therapeutics stock at $21.18, your return over the last 3 years would have been -67.52%, for an annualized return of -31.26% (not including any dividends or dividend reinvestments).

How much is Monte Rosa Therapeutics's stock price per share?

(NASDAQ: GLUE) Monte Rosa Therapeutics stock price per share is $6.88 today (as of Feb 6, 2025).

What is Monte Rosa Therapeutics's Market Cap?

(NASDAQ: GLUE) Monte Rosa Therapeutics's market cap is $422.68M, as of Feb 8, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Monte Rosa Therapeutics's market cap is calculated by multiplying GLUE's current stock price of $6.88 by GLUE's total outstanding shares of 61,436,740.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.